Isentress (Raltegravir Potassium) Patent Expiration, LOE Window & CMS Spending

Isentress (Raltegravir Potassium) by Merck & Co.: FDA Orange Book core substance LOE 2030-06-02 (last listed 2032-03-30), 2 AB generics, $147.0M 2024 CMS Part D & Medicaid spend, and $1,611 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN022145 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-06-02
Last Listed Patent or Exclusivity Date2032-03-30
Orange Book Patents (*PED Extensions)7 patents (2 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$147.0M
2024 Medicare Part D Spend$112.7M
2024 Medicaid Spend$34.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,611 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.